{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:22:44Z","timestamp":1790126564446,"version":"4.0.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023731","name":"Junta de Andalucia Consejer\u00eda de Salud y Familias","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund Plus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud y Familias, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009473","name":"Universidad de M\u00e1laga","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009473","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00427"],"award-info":[{"award-number":["PI22\/00427"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117364","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T03:38:04Z","timestamp":1758685084000},"page":"117364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P3","title":["A synergic GLP-1\/Acylethanolamide-based combined therapy for MAFLD: Studies in rat models"],"prefix":"10.1016","volume":"242","author":[{"given":"Marialuisa de","family":"Ceglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Tovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Rodr\u00edguez-Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gavito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Baixeras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rodr\u00edguez de Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9868-015X","authenticated-orcid":false,"given":"Juan","family":"Decara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117364_b0005","doi-asserted-by":"crossref","unstructured":"Wong, W. K., & Chan, W. K. (2021). Nonalcoholic Fatty Liver Disease: A Global Perspective. Clinical therapeutics, 43(3), 473\u2013499. https:\/\/doi.org\/10.1016\/j.clinthera.2021.01.007 Nakatsuka T, Tateishi R. (2023). Development and prognosis of hepatocellular carcinoma in patients with diabetes. Clin Mol Hepatol, 29(1), 51\u201364.","DOI":"10.1016\/j.clinthera.2021.01.007"},{"issue":"7","key":"10.1016\/j.bcp.2025.117364_b0010","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam, M., Sanyal, A. J., George, J., & International Consensus Panel","year":"2020","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1016\/j.bcp.2025.117364_b0015","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","article-title":"MAFLD: how is it different from NAFLD?","volume":"29","author":"Gofton","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117364_b0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3350\/cmh.2022.0095","article-title":"Development and prognosis of hepatocellular carcinoma in patients with diabetes","volume":"29","author":"Nakatsuka","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.bcp.2025.117364_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.603926","article-title":"Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments","volume":"11","author":"Peng","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117364_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1038475","article-title":"The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease","volume":"9","author":"Gao","year":"2022","journal-title":"Front. Med."},{"issue":"3","key":"10.1016\/j.bcp.2025.117364_b0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.7861\/clinmedicine.18-3-245","article-title":"Non-alcoholic fatty liver disease","volume":"18","author":"Maurice","year":"2018","journal-title":"Clin. Med. (Lond.)"},{"issue":"5","key":"10.1016\/j.bcp.2025.117364_b0040","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1089\/ars.2009.3058","article-title":"Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities","volume":"15","author":"Gambino","year":"2011","journal-title":"Antioxid. Redox Signal."},{"issue":"17","key":"10.1016\/j.bcp.2025.117364_b0045","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"American heart association, & national heart, lung, and blood institute (2005). diagnosis and management of the metabolic syndrome: an american heart association\/national heart, lung, and blood institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2025.117364_b0050","doi-asserted-by":"crossref","unstructured":"Stefano, J. T., Duarte, S. M. B., Ribeiro Leite Altikes, R. G., & Oliveira, C. P. (2023). Non-pharmacological management options for MAFLD: a practical guide. Therapeutic advances in endocrinology and metabolism, 14, 20420188231160394. https:\/\/doi.org\/10.1177\/20420188231160394.","DOI":"10.1177\/20420188231160394"},{"key":"10.1016\/j.bcp.2025.117364_b0055","doi-asserted-by":"crossref","first-page":"e06","DOI":"10.15420\/ecr.2023.34","article-title":"Treatment options and continuity of care in metabolic-associated fatty liver disease: a multidisciplinary approach","volume":"19","author":"Lara-Romero","year":"2024","journal-title":"European Cardiology"},{"key":"10.1016\/j.bcp.2025.117364_b0060","doi-asserted-by":"crossref","DOI":"10.1111\/dom.15898","article-title":"Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: a prospective, multicentre, observational study","author":"Arai","year":"2024","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.bcp.2025.117364_b0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease","volume":"44","author":"Yabut","year":"2023","journal-title":"Endocr. Rev."},{"issue":"6","key":"10.1016\/j.bcp.2025.117364_b0070","first-page":"1735","article-title":"Effects of liraglutide on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis diabetes therapy: research","volume":"12","author":"Song","year":"2021","journal-title":"Treat. Ed. Diabet. Relat. Disorders"},{"issue":"9","key":"10.1016\/j.bcp.2025.117364_b0075","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1507\/endocrj.EJ24-0168","article-title":"Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease","volume":"71","author":"Xu","year":"2024","journal-title":"Endocr. J."},{"key":"10.1016\/j.bcp.2025.117364_b0080","doi-asserted-by":"crossref","unstructured":"Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., LEAN trial team, Abouda, G., Aldersley, M. A., Stocken, D., Gough, S. C., Tomlinson, J. W., Brown, R. M., H\u00fcbscher, S. G., & Newsome, P. N. (2016). Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet (London, England), 387(10019), 679\u2013690. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X.","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"10.1016\/j.bcp.2025.117364_b0085","doi-asserted-by":"crossref","unstructured":"Sumida, Y., Okanoue, T., Nakajima, A., & Japan Study Group of NAFLD (JSG-NAFLD) (2019). Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. Hepatology research: the official journal of the Japan Society of Hepatology, 49(11), 1256\u20131262. https:\/\/doi.org\/10.1111\/hepr.13425.","DOI":"10.1111\/hepr.13425"},{"key":"10.1016\/j.bcp.2025.117364_b0090","doi-asserted-by":"crossref","unstructured":"Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., Drenth, J., Anstee, Q. M., Hum, D., Hanf, R., Roudot, A., Megnien, S., Staels, B., Sanyal, A., & GOLDEN-505 Investigator Study Group (2016). Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-\u03b1 and -\u03b4, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology, 150(5), 1147\u20131159.e5. https:\/\/doi.org\/10.1053\/j.gastro.2016.01.038.","DOI":"10.1053\/j.gastro.2016.01.038"},{"issue":"3","key":"10.1016\/j.bcp.2025.117364_b0095","doi-asserted-by":"crossref","first-page":"433","DOI":"10.21037\/hbsn-21-579","article-title":"Pan-peroxisome proliferator-activated receptor agonist lanifibranor as a dominant candidate pharmacological therapy for nonalcoholic fatty liver disease","volume":"11","author":"Yoneda","year":"2022","journal-title":"Hepatobiliary Surgery Nutrit."},{"key":"10.1016\/j.bcp.2025.117364_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.984041","article-title":"Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?","volume":"13","author":"Tsankof","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117364_b0105","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1023\/B:PHAM.0000041444.06122.8d","article-title":"Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future","volume":"21","author":"van Raalte","year":"2004","journal-title":"Pharm. Res."},{"issue":"10","key":"10.1016\/j.bcp.2025.117364_b0110","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1242\/dmm.019919","article-title":"Treatment with a novel oleic-acid-dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats","volume":"8","author":"Decara","year":"2015","journal-title":"Dis. Model. Mech."},{"issue":"20","key":"10.1016\/j.bcp.2025.117364_b0115","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.3390\/nu15204448","article-title":"Administration of linoleoylethanolamide reduced weight gain, dyslipidemia, and inflammation associated with high-fat-diet-induced obesity","volume":"15","author":"Tovar","year":"2023","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.bcp.2025.117364_b0120","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1021\/acsptsci.4c00105","article-title":"Hydroxytyrosol linoleoyl ether ameliorates metabolic-associated fatty liver disease symptoms in obese zucker rats","volume":"7","author":"Tovar","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"6953","key":"10.1016\/j.bcp.2025.117364_b0125","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature01921","article-title":"Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha","volume":"425","author":"Fu","year":"2003","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2025.117364_b0130","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.neuropharm.2006.03.029","article-title":"Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole\u2013LH 21","volume":"51","author":"Pavon","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2025.117364_b0135","doi-asserted-by":"crossref","unstructured":"Alonso M, Serrano A, Vida M, Crespillo A, Hernandez-Folgado L, Jagerovic N, Goya P, Reyes-Cabello C, Perez-Valero V, Decara J, Mac\u00edas-Gonz\u00e1lez M, Berm\u00fadez-Silva FJ, Su\u00e1rez J, Rodr\u00edguez de Fonseca F, Pav\u00f3n FJ. Anti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats. Br J Pharmacol. 2012 Apr;165(7):2274-91. doi: 10.1111\/j.1476-5381.2011.01698.x. PMID: 21951309; PMCID: PMC3413862.","DOI":"10.1111\/j.1476-5381.2011.01698.x"},{"issue":"3","key":"10.1016\/j.bcp.2025.117364_b0140","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1172\/JCI17725","article-title":"The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis","volume":"112","author":"Cota","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2025.117364_b0145","doi-asserted-by":"crossref","unstructured":"Osei-Hyiaman, D., Harvey-White, J., B\u00e1tkai, S., & Kunos, G. (2006). The role of the endocannabinoid system in the control of energy homeostasis. International journal of obesity (2005), 30 Suppl 1, S33\u2013S38. https:\/\/doi.org\/10.1038\/sj.ijo.0803276.","DOI":"10.1038\/sj.ijo.0803276"},{"issue":"5","key":"10.1016\/j.bcp.2025.117364_b0150","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1124\/mol.111.072769","article-title":"Rimonabant, a cannabinoid receptor type 1 inverse agonist, inhibits hepatocyte lipogenesis by activating liver kinase B1 and AMP-activated protein kinase axis downstream of G\u03b1 i\/o inhibition","volume":"80","author":"Wu","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117364_b0155","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/978-3-642-24716-3_17","article-title":"Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight","volume":"209","author":"Engeli","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"issue":"20","key":"10.1016\/j.bcp.2025.117364_b0160","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.3390\/molecules26206178","article-title":"The peripheral cannabinoid receptor type 1 (CB1) as a molecular target for modulating body weight in man","volume":"26","author":"O'Sullivan","year":"2021","journal-title":"Molecules (basel, Switzerland)"},{"key":"10.1016\/j.bcp.2025.117364_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101087","article-title":"Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53\/miRNA-22\/SIRT1\/PPAR\u03b1 dependent","volume":"42","author":"Azar","year":"2020","journal-title":"Mol. Metab."},{"key":"10.1016\/j.bcp.2025.117364_b0170","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bcp.2018.09.008","article-title":"PPAR\u03b1\/CB1 receptor dual ligands as a novel therapy for alcohol use disorder: evaluation of a novel oleic acid conjugate in preclinical rat models","volume":"157","author":"Alen","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2025.117364_b0175","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/cmdc.201000161","article-title":"Synthesis of fatty acid amides of catechol metabolites that exhibit antiobesity properties","volume":"5","author":"Almeida","year":"2010","journal-title":"ChemMedChem"},{"issue":"16","key":"10.1016\/j.bcp.2025.117364_b0180","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1111\/bph.15193","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"177","author":"Percie du Sert","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117364_b0185","first-page":"660","article-title":"Elaidyl-sulfamide, an oleoylethanolamide-modelled PPAR\u03b1 agonist, reduces body weight gain and plasma cholesterol in rats","volume":"5","author":"Decara","year":"2012","journal-title":"Dis. Model. Mech."},{"issue":"6","key":"10.1016\/j.bcp.2025.117364_b0190","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.3390\/ijms26062420","article-title":"A combined GLP-1\/PPARa\/CB1-based therapy to restore the central and peripheral metabolic dysregulation induced by a high-fructose high-fat diet","volume":"26","author":"de Ceglia","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117364_b0195","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/clinchem\/36.1.15","article-title":"Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints","volume":"36","author":"Warnick","year":"1990","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2025.117364_b0200","doi-asserted-by":"crossref","first-page":"9858","DOI":"10.1038\/s41598-018-27871-7","article-title":"The adiponectin promoter activator NP-1 induces high levels of circulating TNF\u03b1 and weight loss in obese (fa\/fa) Zucker rats","volume":"8","author":"Decara","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.117364_b0205","doi-asserted-by":"crossref","unstructured":"Ostawal, A., Mocevic, E., Kragh, N., & Xu, W. (2016). Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review. Diabetes therapy: research, treatment and education of diabetes and related disorders, 7(3), 411\u2013438. https:\/\/doi.org\/10.1007\/s13300-016-0180-0.","DOI":"10.1007\/s13300-016-0180-0"},{"issue":"6","key":"10.1016\/j.bcp.2025.117364_b0210","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/biof.1295","article-title":"Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators","volume":"42","author":"Decara","year":"2016","journal-title":"BioFactors (oxford, England)"},{"issue":"7","key":"10.1016\/j.bcp.2025.117364_b0215","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1021\/acs.jmedchem.1c01842","article-title":"Discovery of V-0219: a small-molecule positive allosteric modulator of the glucagon-like peptide-1 receptor toward oral treatment for \u201cdiabesity\u201d","volume":"65","author":"Decara","year":"2022","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2025.117364_b0220","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.3390\/nu13082589","article-title":"Palmitoleoylethanolamide is an Efficient Anti-Obesity Endogenous compound: comparison with Oleylethanolamide in Diet-Induced Obesity","volume":"13","author":"Tovar","year":"2021","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.bcp.2025.117364_b0225","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.neuropharm.2007.03.007","article-title":"The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats","volume":"54","author":"Serrano","year":"2008","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.bcp.2025.117364_b0230","doi-asserted-by":"crossref","first-page":"R595","DOI":"10.1152\/ajpregu.00459.2017","article-title":"Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice","volume":"315","author":"Brown","year":"2018","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117364_b0235","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2337\/db20-0162","article-title":"CB1 and GLP-1 receptors cross talk provides new therapies for obesity","volume":"70","author":"Zizzari","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2025.117364_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102661","article-title":"GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study","volume":"73","author":"Moll","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"6706","key":"10.1016\/j.bcp.2025.117364_b0245","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1126\/science.adn4128","article-title":"The benefits of GLP-1 drugs beyond obesity","volume":"385","author":"Drucker","year":"2024","journal-title":"Science (New York, N.Y.)"},{"issue":"4","key":"10.1016\/j.bcp.2025.117364_b0250","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/1440-1681.13238","article-title":"A systematic review of the effects of oleoylethanolamide, a high-affinity endogenous ligand of PPAR-\u03b1, on the management and prevention of obesity","volume":"47","author":"Tutunchi","year":"2020","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"10","key":"10.1016\/j.bcp.2025.117364_b0255","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/ph14101002","article-title":"Obesity as a condition determined by food addiction: should brain endocannabinoid system alterations be the cause and its modulation the solution?","volume":"14","author":"de Ceglia","year":"2021","journal-title":"Pharmaceuticals (basel, Switzerland)"},{"issue":"2","key":"10.1016\/j.bcp.2025.117364_b0260","first-page":"102","article-title":"Cannabinoid receptors in metabolic regulation and diabetes","volume":"36","author":"Rohbeck","year":"2021","journal-title":"Physiology (Bethesda)"},{"issue":"4","key":"10.1016\/j.bcp.2025.117364_b0265","first-page":"395","article-title":"Combined stimulation of glucagon-like peptide-1 receptor and inhibition of cannabinoid CB1 receptor act synergistically to reduce food intake and body weight in the rat","volume":"62","author":"Bojanowska","year":"2011","journal-title":"J. Physiol. Pharmacol. Off. J. Polish Physiol. Soc."},{"issue":"6","key":"10.1016\/j.bcp.2025.117364_b0270","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40262-015-0343-6","article-title":"Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics","volume":"55","author":"Jacobsen","year":"2016","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.bcp.2025.117364_b0275","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/hep.31897","article-title":"A systematic review of animal models of NAFLD finds high-fat, high-fructose diets most closely resemble human NAFLD","volume":"74","author":"Im","year":"2021","journal-title":"Hepatology (Baltimore Md.)"},{"issue":"2","key":"10.1016\/j.bcp.2025.117364_b0280","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/aps.2011.168","article-title":"Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats","volume":"33","author":"Hansen","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"issue":"10","key":"10.1016\/j.bcp.2025.117364_b0285","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2337\/db09-1564","article-title":"Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats","volume":"59","author":"Cummings","year":"2010","journal-title":"Diabetes"},{"issue":"128","key":"10.1016\/j.bcp.2025.117364_b0290","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.appet.2018.05.129","article-title":"Oleoylethanolamide increases the expression of PPAR-\u0391 and reduces appetite and body weight in obese people: a clinical trial","volume":"1","author":"Laleh","year":"2018","journal-title":"Appetite"},{"key":"10.1016\/j.bcp.2025.117364_b0295","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/132960","article-title":"Peroxisome proliferator activated receptors and lipoprotein metabolism","volume":"2008","author":"Kersten","year":"2008","journal-title":"PPAR Res."},{"issue":"8","key":"10.1016\/j.bcp.2025.117364_b0300","first-page":"961","article-title":"PPARalpha and dyslipidemia","volume":"1771","author":"Duval","year":"2007","journal-title":"BBA"},{"issue":"11","key":"10.1016\/j.bcp.2025.117364_b0305","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.metabol.2013.06.011","article-title":"Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats","volume":"62","author":"Merroun","year":"2013","journal-title":"Metab. Clin. Exp."},{"issue":"9","key":"10.1016\/j.bcp.2025.117364_b0310","doi-asserted-by":"crossref","first-page":"470","DOI":"10.4254\/wjh.v5.i9.470","article-title":"Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease","volume":"5","author":"Kostapanos","year":"2013","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.bcp.2025.117364_b0315","doi-asserted-by":"crossref","first-page":"2S28","DOI":"10.1016\/S1262-3636(17)30070-8","article-title":"GLP-1 receptor agonists in NAFLD","volume":"43 Suppl 1","author":"Petit","year":"2017","journal-title":"Diabetes Metab."},{"issue":"1","key":"10.1016\/j.bcp.2025.117364_b0320","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000282100","article-title":"Endocannabinoids and their role in fatty liver disease","volume":"28","author":"Mallat","year":"2010","journal-title":"Dig. Dis."},{"issue":"13","key":"10.1016\/j.bcp.2025.117364_b0325","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116506119","article-title":"Structural determinants of dual incretin receptor agonism by tirzepatide","volume":"119","author":"Sun","year":"2022","journal-title":"PNAS"},{"issue":"9","key":"10.1016\/j.bcp.2025.117364_b0330","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1111\/dom.15167","article-title":"The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying","volume":"25","author":"Urva","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.bcp.2025.117364_b0335","first-page":"100","article-title":"The effects of liraglutide on liver enzymes and metabolic factors in patients with nonalcoholic steatohepatitis: a meta-analysis of randomized controlled trials","volume":"18","author":"Malik","year":"2023","journal-title":"Przeglad Gastroenterologiczny"},{"issue":"4","key":"10.1016\/j.bcp.2025.117364_b0340","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5114\/aoms.2016.58928","article-title":"Obesity and inflammation: the linking mechanism and the complications","volume":"13","author":"Ellulu","year":"2017","journal-title":"Arch. Med. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2025.117364_b0345","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s11154-024-09884-y","article-title":"Pro- and anti-inflammatory cytokines are the game-changers in childhood obesity-associated metabolic disorders (diabetes and non-alcoholic fatty liver diseases)","volume":"25","author":"Ullah","year":"2024","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"3","key":"10.1016\/j.bcp.2025.117364_b0350","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117364_b0355","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nn1457","article-title":"Endocannabinoid control of food intake and energy balance","volume":"8","author":"Di Marzo","year":"2005","journal-title":"Nat. Neurosci."},{"issue":"4","key":"10.1016\/j.bcp.2025.117364_b0360","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.bcp.2025.117364_b0365","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular actions of PPAR\u03b1 in lipid metabolism and inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocr. Rev."},{"issue":"12","key":"10.1016\/j.bcp.2025.117364_b0370","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/14779072.2017.1408410","article-title":"Fibrates in the management of atherogenic dyslipidemia","volume":"15","author":"Okopie\u0144","year":"2017","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.bcp.2025.117364_b0375","doi-asserted-by":"crossref","unstructured":"Despr\u00e9s, J. P., Golay, A., Sj\u00f6str\u00f6m, L., & Rimonabant in Obesity-Lipids Study Group (2005). Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. The New England journal of medicine, 353(20), 2121\u20132134. https:\/\/doi.org\/10.1056\/NEJMoa044537.","DOI":"10.1056\/NEJMoa044537"},{"issue":"3","key":"10.1016\/j.bcp.2025.117364_b0380","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4093\/dmj.2023.0277","article-title":"Glucagon-like peptide-1: new regulator in lipid metabolism","volume":"48","author":"Bu","year":"2024","journal-title":"Diabetes Metab. J."},{"issue":"1","key":"10.1016\/j.bcp.2025.117364_b0385","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2174\/0929867327666200303122734","article-title":"The effect of CB1 antagonism on hepatic oxidative\/nitrosative stress and inflammation in nonalcoholic fatty liver disease","volume":"28","author":"Jorga\u010devi\u0107","year":"2021","journal-title":"Curr. Med. Chem."},{"issue":"11\u201312","key":"10.1016\/j.bcp.2025.117364_b0390","first-page":"1285","article-title":"Cannabinoid receptor type I modulates alcohol-induced liver fibrosis. Molecular medicine (Cambridge","volume":"17","author":"Patsenker","year":"2011","journal-title":"Mass.)"},{"issue":"8","key":"10.1016\/j.bcp.2025.117364_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2023.100794","article-title":"Monoacylglycerol lipase reprograms hepatocytes and macrophages to promote liver regeneration","volume":"5","author":"Allaire","year":"2023","journal-title":"JHEP Reports: Innovat. Hepatol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117364_b0400","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.3390\/ijms12053117","article-title":"Inflammation, oxidative stress, and obesity","volume":"12","author":"Fern\u00e1ndez-S\u00e1nchez","year":"2011","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117364_b0405","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.595371","article-title":"Oxidative stress in non-alcoholic fatty liver disease an updated mini review","volume":"8","author":"Delli Bovi","year":"2021","journal-title":"Front. Med."},{"issue":"3","key":"10.1016\/j.bcp.2025.117364_b0410","doi-asserted-by":"crossref","first-page":"479","DOI":"10.15171\/apb.2018.056","article-title":"Oleoylethanolamide supplementation reduces inflammation and oxidative stress in obese people: a clinical trial","volume":"8","author":"Payahoo","year":"2018","journal-title":"Adv. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.bcp.2025.117364_b0415","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1038\/s41598-017-06712-z","article-title":"GLP-1 inhibits high-glucose-induced oxidative injury of vascular endothelial cells","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.117364_b0420","doi-asserted-by":"crossref","unstructured":"Teskey, G., Abrahem, R., Cao, R., Gyurjian, K., Islamoglu, H., & Lucero, M., Martinez A. (2018). Chapter Five - Glutathione as a Marker for Human Disease. In G. S. Makowski (Ed.), Advances in Clinical Chemistry (Vol. 87, pp. 141-159): Elsevier. https:\/\/doi.org\/10.1016\/bs.acc.2018.07.004.","DOI":"10.1016\/bs.acc.2018.07.004"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522500629X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522500629X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:32:12Z","timestamp":1773131532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522500629X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":84,"alternative-id":["S000629522500629X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117364","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A synergic GLP-1\/Acylethanolamide-based combined therapy for MAFLD: Studies in rat models","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117364","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117364"}}